Safety, antiviral activity, and pharmacokinetics of long-acting cabotegravir plus long-acting rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): week 96 and end-of-study results from a multinational, phase 1/2, single-arm trial

The Lancet Child & Adolescent Health · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles